GRFS: Grifols SA Price to Sales
The calculated price-to-sales ratio demonstrates the position of Grifols, S.A. (GRFS) as a global leader in the B2B plasma-derived medicines segment with a high market share in rare pathologies. The value of 0.30 shows the latest metric value amid cost reductions and growth in raw material collection. High barriers to entry and resource scarcity allow the issuer to effectively manage the pricing power of life-saving medications.
Analytical breakdowns for Grifols Group (GRFS)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
- earnings and market multiples details:
GRFS - Net Income|Expected Net Income Grifols, S.A.|GRFS - Price to Earnings Ratio|Market Cap to Projected Earnings Grifols SA|GRFS - Price/Earnings to Growth Multiple|Total Company Value to Operating Income Before Depreciation Ratio Grifols Group|GRFS - Operating profit EBITDA|Net earnings per share (EPS TTM) Grifols|GRFS - Net earnings per share for the last 12 months|Year-over-year net earnings per share change for the last twelve months grifols.com|GRFS - Earnings growth in current year|Net earnings per one share growth forecast for next year Grifols, S.A.
- total revenue and sales volume data:
Fundamental company analysis:GRFS - grifols.com
Grifols, S.A. (GRFS) generates revenue through the sale of high-tech plasma derivatives and diagnostic equipment, making the P/S ratio a key indicator for valuing the business's market capitalization relative to its operational volumes. The current value of 0.30 reflects investors' willingness to pay per unit of sales, while current P/S dynamics allow for a comparison of this multiple against historical extremes to identify whether the asset is overbought or undervalued.
Competitors of Grifols, S.A.
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA Bio - P/S Multiple|Price-to-Revenue Multiple Protagonist Corp (PTGX)|Immunovant, Inc. (IMVT) - Price-to-Revenue Ratio|kiniksa.com - Market Capitalization-to-Revenue Ratio|ADPT (Adaptive Biotechnologies Corporation) - P/S Multiple|Celldex Therapeutics Inc (CLDX) - Price-to-Revenue Coefficient|P/S Multiple AUPH|BCRX: Price-to-Sales Ratio|Price-to-Revenue Ratio Vera Therapeutics, Inc. VERA|dianthustx.com (DNTH) - Price to Sales|PHVS - Price-to-Revenue Ratio|ABCL: Price-to-Revenue Ratio|Tourmaline Corp (TRML) - Price-to-Revenue Ratio|PGEN - Price-to-Revenue Coefficient|Market Cap to Revenue PHAR|NKTR: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Upstream Bio (UPB)|Price-to-Revenue Coefficient Zenas Bio|Immunome Corp - Market Cap to Revenue|Price-to-Revenue Coefficient Gossamer Bio Corp. (GOSS)|KalVista Pharmaceuticals - P/S Multiple|SEPN - P/S Multiple|PVLA (Pieris Pharmaceuticals, Inc.) - Market Cap to Revenue|SVRA - Price-to-Revenue Coefficient|RIGL (Rigel Pharmaceuticals Inc) - P/S Multiple|ANAB - Price-to-Revenue Multiple|Price-to-Revenue Ratio Astria Therapeutics (ATXS)|ENGN (engene.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple RAPT (RAPT Therapeutics)|JBIO (Aerovate Therapeutics, Inc.) - Price-to-Sales Ratio|ACRS - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Kyverna Therapeutics, Inc KYTX|Tiziana Life Sciences (TLSA) - Price-to-Revenue Ratio|Price-to-Sales Ratio CABA (cabalettabio.com)|VTYX (Ventyx Biosciences, Inc.) - P/S Multiple|THTX: Market Capitalization-to-Revenue Ratio|P/S Multiple AVTX|P/S Multiple Eledon Pharmaceuticals, Inc (ELDN)|Price-to-Revenue Ratio Agenus AGEN|Market Capitalization-to-Revenue Ratio CLYM|ZURA - Price-to-Revenue Ratio|aTyr Pharma Inc (ATYR) - Market Cap to Revenue|ADAG: P/S Multiple|Ikena Oncology (IMA) - P/S Multiple|Market Cap to Revenue STTK|EQ: Market Capitalization-to-Revenue Ratio|P/S Multiple CNTB|Price-to-Revenue Coefficient immunic-therapeutics.com|Price-to-Revenue Ratio Atara Bio ATRA|IFRX - Market Cap to Revenue|XFOR - Price-to-Revenue Ratio|Adicet Bio (ACET) - Market Cap to Revenue|CELU (celularity.com) - Market Cap to Revenue|INmune Bio Inc (INMB) - P/S Multiple|Price-to-Revenue Ratio Barinthus Bio|Market Cap to Revenue Ratio KZR (Kezar Life Sciences Inc)|P/S Multiple SABS|AKTX - Price to Sales|P/S Multiple ENLV (Enlivex Therapeutics Ltd.)|Price-to-Revenue Multiple Q32 Bio Inc|GOVX - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio EDSA (Edesa Biotech Corp)|IBIO: P/S Multiple|CARM - Price-to-Revenue Coefficient|XTLB (XTL Biopharmaceuticals Ltd.) - P/S Multiple|Bolt Bio - Price-to-Sales Ratio|Price-to-Revenue Ratio HCW Biologics Inc. (HCWB)|APVO - Price to Sales|Price-to-Revenue Ratio AIM ImmunoTech Inc. AIM|Aditxt Inc. - Price-to-Revenue Ratio|GRI - Price-to-Revenue Ratio|Price-to-Revenue Coefficient XORTX Therapeutics Inc XRTX|HIND (ReShape Lifesciences) - Market Cap to Revenue|Revelation Biosciences Corp - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Indaptus Therapeutics|scinai.com (SCNI) - Price-to-Revenue Coefficient|Market Cap to Revenue CALI (CalciMedica, Inc.)|Price-to-Revenue Coefficient affimed.com|P/S Multiple ALLK (Allakos)|P/S Multiple HOOKIPA Pharma, Inc. HOOK|IGMS: Market Cap to Revenue|Price-to-Revenue Coefficient iteostherapeutics.com ITOS|OCEA: P/S Multiple|Price-to-Revenue Multiple TC BioPharm (Holdings) Plc TCBP|Price-to-Revenue Ratio Third Harmonic Bio, Inc
